Biology of incretins: GLP-1 and GIP - PubMed (original) (raw)

Review

Biology of incretins: GLP-1 and GIP

Laurie L Baggio et al. Gastroenterology. 2007 May.

Abstract

This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was reviewed, with emphasis on recent advances in our understanding of the biology of GIP and GLP-1. GIP and GLP-1 are both secreted within minutes of nutrient ingestion and facilitate the rapid disposal of ingested nutrients. Both peptides share common actions on islet beta-cells acting through structurally distinct yet related receptors. Incretin-receptor activation leads to glucose-dependent insulin secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis. GIP also promotes energy storage via direct actions on adipose tissue, and enhances bone formation via stimulation of osteoblast proliferation and inhibition of apoptosis. In contrast, GLP-1 exerts glucoregulatory actions via slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion. GLP-1 also promotes satiety and sustained GLP-1-receptor activation is associated with weight loss in both preclinical and clinical studies. The rapid degradation of both GIP and GLP-1 by the enzyme dipeptidyl peptidase-4 has led to the development of degradation-resistant GLP-1-receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. These agents decrease hemoglobin A1c (HbA1c) safely without weight gain in subjects with type 2 diabetes. GLP-1 and GIP integrate nutrient-derived signals to control food intake, energy absorption, and assimilation. Recently approved therapeutic agents based on potentiation of incretin action provide new physiologically based approaches for the treatment of type 2 diabetes.

PubMed Disclaimer

Similar articles

• The biology of incretin hormones.
  Drucker DJ. Drucker DJ. Cell Metab. 2006 Mar;3(3):153-65. doi: 10.1016/j.cmet.2006.01.004. Cell Metab. 2006. PMID: 16517403 Review.
• GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
  Hansotia T, Drucker DJ. Hansotia T, et al. Regul Pept. 2005 Jun 15;128(2):125-34. doi: 10.1016/j.regpep.2004.07.019. Regul Pept. 2005. PMID: 15780432 Review.
• Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
  Yabe D, Seino Y. Yabe D, et al. Prog Biophys Mol Biol. 2011 Nov;107(2):248-56. doi: 10.1016/j.pbiomolbio.2011.07.010. Epub 2011 Jul 28. Prog Biophys Mol Biol. 2011. PMID: 21820006 Review.
• The entero-insular axis: implications for human metabolism.
  Ranganath LR. Ranganath LR. Clin Chem Lab Med. 2008;46(1):43-56. doi: 10.1515/CCLM.2008.008. Clin Chem Lab Med. 2008. PMID: 18020966 Review.
• Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
  Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ. Maida A, et al. Gastroenterology. 2009 Dec;137(6):2146-57. doi: 10.1053/j.gastro.2009.09.004. Epub 2009 Sep 17. Gastroenterology. 2009. PMID: 19766644

Cited by

• Advances in pharmacologic therapies for type 2 diabetes.
  Morsink LM, Smits MM, Diamant M. Morsink LM, et al. Curr Atheroscler Rep. 2013 Feb;15(2):302. doi: 10.1007/s11883-012-0302-8. Curr Atheroscler Rep. 2013. PMID: 23299642 Review.
• Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons.
  Voss U, Sand E, Hellström PM, Ekblad E. Voss U, et al. BMC Gastroenterol. 2012 Apr 1;12:30. doi: 10.1186/1471-230X-12-30. BMC Gastroenterol. 2012. PMID: 22463807 Free PMC article.
• Modeling of glucose-induced cAMP oscillations in pancreatic β cells: cAMP rocks when metabolism rolls.
  Peercy BE, Sherman AS, Bertram R. Peercy BE, et al. Biophys J. 2015 Jul 21;109(2):439-49. doi: 10.1016/j.bpj.2015.06.024. Biophys J. 2015. PMID: 26200880 Free PMC article.
• Proglucagon-Derived Peptides as Therapeutics.
  Lafferty RA, O'Harte FPM, Irwin N, Gault VA, Flatt PR. Lafferty RA, et al. Front Endocrinol (Lausanne). 2021 May 18;12:689678. doi: 10.3389/fendo.2021.689678. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34093449 Free PMC article. Review.
• Islet α cells and glucagon--critical regulators of energy homeostasis.
  Campbell JE, Drucker DJ. Campbell JE, et al. Nat Rev Endocrinol. 2015 Jun;11(6):329-38. doi: 10.1038/nrendo.2015.51. Epub 2015 Apr 7. Nat Rev Endocrinol. 2015. PMID: 25850661 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database